Last reviewed · How we verify

NCT03879616

Optimizing Gastrointestinal Procedure Appointments

Completed NA Last updated 21 February 2022
What this trial tests

NA trial testing An Enhanced Reminder in Gastrointestinal Disease in 15,974 participants. Completed in 31 December 2021.

Timeline
8 March 2019
Primary endpoint
8 September 2019
31 December 2021

Quick facts

Lead sponsorKaiser Permanente
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposehealth services research
Enrollment15,974
Start date8 March 2019
Primary completion8 September 2019
Estimated completion31 December 2021
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Kaiser Permanente — full company profile →

Who can join

Adults 21 to 120, any sex, with Gastrointestinal Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project will address the question: Does an "enhanced" IVR-T protocol differ in effectiveness from the standard IVR-T protocol in reducing missed appointments and late cancellations for GI endoscopy? Hypothesis: The enhanced IVR-T protocol will be more effective.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Gastrointestinal Disease

Currently open trials in the same condition.

Other Kaiser Permanente trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03879616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing